621 related articles for article (PubMed ID: 21115860)
1. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
3. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K; Nakagami K; Mizutani M; Hozumi Y; Fujiwara Y; Masuda N; Tsukamoto F; Saito M; Miura S; Eguchi K; Shinkai T; Ando M; Watanabe T; Masuda N; Ohashi Y; Sano M; Noguchi S
Breast Cancer Res Treat; 2010 Jan; 119(1):127-36. PubMed ID: 19690954
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
6. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Servitja S; Ramos M; Gil M; Sánchez-Rovira P; Vázquez-Estevez S; Virizuela JA; García-Estevez L; Velasco A; Tusquets I
Anticancer Drugs; 2012 Feb; 23(2):239-46. PubMed ID: 22112931
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
20. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
